UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549


Form 8-K


CURRENT REPORT   Pursuant to
Section 13 or 15( d ) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2017


Vermillion, Inc.

(Exact Name of Registrant as Specified in Charter)




 

 

Delaware

001-34810

33-0595156

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

12117 Bee Caves Road Building Three, Suite 100, Austin, TX 78738  

(Address of Principal Executive Offices) (Zip Code)

(512) 519-0400

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 


 

Item 1.01 Entry into a Material Definitive Agreement.

Vermillion, Inc., a Delaware corporation, and its wholly-owned subsidiary, ASPiRA LABS, Inc., a Delaware corporation, entered into an Amendment No. 2 to Testing and Services Agreement (the “Amendment”) with Quest Diagnostics Incorporated, a Delaware corporation, effective March 11, 2017. The Amendment, executed as of March 7, 2017, amends that certain Testing and Services Agreement, dated as of March 11, 2015, as amended by that certain Amendment No. 1 to Testing and Services Agreement, dated as of April 10, 2015 (as so amended, the “TSA”). The primary purpose of the Amendment was to extend the initial term of the TSA from March 11, 2017 to March 11, 2018.

The foregoing information is qualified in its entirety by reference to the Amendment, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



10.1 Amendment No. 2 to Testing and Services Agreement, executed as of March 7, 2017 and effective as of March 11, 2017, by and among Vermillion, Inc., ASPiRA LABS, Inc. and Quest Diagnostics Incorporated.





 


 



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.









 



Vermillion, Inc.

Date: March 13, 2017

By:

/s/ Eric J. Schoen



 

Eric J. Schoen

 

Senior Vice President, Finance and Chief Accounting Officer




 

EXHIBIT INDEX



No. Document



10.1 Amendment No. 2 to Testing and Services Agreement, executed as of March 7, 2017 and effective as of March 11, 2017, by and among Vermillion, Inc., ASPiRA LABS, Inc. and Quest Diagnostics Incorporated.




 

 

 

 

 

Exhibit 10 .1

 



AMENDMENT NO. 2 TO TESTING AND SERVICES AGREEMENT



THIS AMENDMENT NO. 2 TO TESTING AND SERVICES AGREEMENT (this “Amendment”) is made and entered into as of this 1st day of March, and effective March 11, 2017 or any other date mutually agreed by the Parties (the “Amendment Effective Date”) by and between Quest Diagnostics Incorporated , a Delaware corporation (“Quest Diagnostics”) on the one hand, and Vermillion, Inc ., a Delaware corporation and ASPiRA Labs , a Delaware corporation and wholly owned subsidiary of Vermillion, Inc. (collectively “Vermillion”) on the other hand, with respect to that certain Testing and Services Agreement dated as of March 11, 2015, and that certain Amendment No. 1 to Testing and Services Agreement dated as of April 10, 2015  (together, the “TSA”).  Capitalized terms used and not otherwise defined herein are used with the meanings attributed to them in the TSA.  All references to section numbers refer to section numbers in the TSA.



WITNESSETH:

NOW THEREFORE, in consideration of the premises and the mutual agreements contained herein, the parties agree the TSA is hereby amended as follows:

1.

Section 5.3 of the TSA is hereby deleted in its entirety and the following new Section 5.3 is substituted in its place:



5.3 This agreement shall terminate in three years from the Effective Date and shall renew for an additional one-year period thereafter by the written agreement of the Parties at least 60 days prior to such renewal date. 



2.

Section 8.3 is hereby replaced with the following new Section 8.3, effective as of the Amendment Effective Date:

8.3 Vermillion shall maintain or cause to be maintained a true and correct set of records pertaining to the performance of all OVA1 Tests under this Agreement. Vermillion shall provide designated Quest contacts a report within 10 business days of the end of each month of Business Unit (BU) volume for the preceding month listing:

a. Number of specimens received through Quest services;

b. List of Quest RBUs or JVs who are the sending sites;

c. Total amount to remit to Quest for payment of services; and


 

d. One check to cover all amounts owed to Quest for all specimens delivered to ASPiRA Labs under the TSA. 

The Parties will work together to establish the format and fields for such report.

3.

The following new Section 8.9 is inserted into the TSA, effective as of the Amendment Effective Date:



8.9 During the term of this Agreement and for a period of three (3) years thereafter, no more than one time per calendar year, Vermillion agrees to permit an accountant selected and paid by Quest and reasonably acceptable to Vermillion to have access during ordinary business hours to such records as are maintained by Vermillion as may be necessary, in the opinion of such accountant, to determine the correctness of any report and/or payment made under this Agreement. In the event that the audit reveals an underpayment of royalty by more than five percent (5%), the cost of the audit shall be paid by Vermillion. If the underpayment is less than five percent (5%), Quest shall pay the cost of the independent audit.  In the event the audit reveals an overpayment by Vermillion, Quest will reimburse Vermillion accordingly. Such accountant shall maintain in confidence, and shall not disclose to Quest, any information concerning Vermillion or its operations or properties other than information directly relating to the correctness of such reports and payments.



[Intentionally left blank]




 

IN WITNESS WHEREOF, the parties intending to be legally bound, have set their hands the date and year first above written.





 

 

 

 

 

 

QUEST DIAGNOSTICS INCORPORATED

 

VERMlLLION, INC.

By:

/s/ Kristie Dolon

 

By:

/s/ Valerie Palmieri

Print Name:

Kristie Dolon

 

Print Name:

Valerie Palmieri

Title:

GM WH

 

Title:

CEO & President

Date:

3/7/17

 

D ate:

3/1/17







ASPIRA LABS, INC.

By:

/s/ Valerie Palmieri

Print Name:

Valerie Palmieri

Title:

CEO & President

Date:

3/1/17